Using a combination of the two drugs, several proteins associated with the basal subtype of bladder cancers were consistently decreased within both cell lines such as KRT1, KRT14, KRT16, P63, and TFAP2A. The gene discussed is TFAP2A; the disease is urinary bladder cancer.